CN110167554A - 一种具有抗癌作用的化合物及其制备方法和应用 - Google Patents

一种具有抗癌作用的化合物及其制备方法和应用 Download PDF

Info

Publication number
CN110167554A
CN110167554A CN201780071039.4A CN201780071039A CN110167554A CN 110167554 A CN110167554 A CN 110167554A CN 201780071039 A CN201780071039 A CN 201780071039A CN 110167554 A CN110167554 A CN 110167554A
Authority
CN
China
Prior art keywords
alkyl
alkoxy
cancer
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780071039.4A
Other languages
English (en)
Other versions
CN110167554B (zh
Inventor
龚兆龙
林毅晖
李风庆
唐方强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thinkti Beijing Pharmaceutical Technology Co ltd
Original Assignee
Thinkti Beijing Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thinkti Beijing Pharmaceutical Technology Co ltd filed Critical Thinkti Beijing Pharmaceutical Technology Co ltd
Publication of CN110167554A publication Critical patent/CN110167554A/zh
Application granted granted Critical
Publication of CN110167554B publication Critical patent/CN110167554B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供一种式I结构的化合物及其制备方法和治疗癌症的用途。本发明化合物对多种癌细胞具有抑制作用，可在体外(血浆中)经生物学转化为活性药物Linifanib，以更低剂量抑制肿瘤细胞尤其是肝癌细胞的增殖。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201780071039.4A 2016-11-17 2017-11-17 一种具有抗癌作用的化合物及其制备方法和应用 Active CN110167554B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611027194.X 2016-11-17
CN201611027194 2016-11-17
PCT/CN2017/111649 WO2018090974A1 (zh) 2016-11-17 2017-11-17 一种具有抗癌作用的化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN110167554A true CN110167554A (zh) 2019-08-23
CN110167554B CN110167554B (zh) 2023-05-23

Family

ID=62145241

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071039.4A Active CN110167554B (zh) 2016-11-17 2017-11-17 一种具有抗癌作用的化合物及其制备方法和应用

Country Status (5)

Country Link
US (1) US11712434B2 (zh)
EP (1) EP3542796B1 (zh)
JP (1) JP6999960B2 (zh)
CN (1) CN110167554B (zh)
WO (2) WO2018090974A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109400597B (zh) * 2018-11-08 2020-07-28 西安交通大学 一种基于vegfr-2抑制剂abt-869的蛋白降解靶向嵌合体及制备方法和应用
WO2022026380A1 (en) * 2020-07-29 2022-02-03 Board Of Regents, The University Of Texas System Urea inhibitors of micro-rna

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072581A (zh) * 2004-10-05 2007-11-14 健泰科生物技术公司 具有减少的毒性的治疗剂
US20100143296A1 (en) * 2008-12-10 2010-06-10 Auspex Pharmaceuticals, Inc. Podophyllotoxin inhibitors of topoisomerase ii
CN102171187A (zh) * 2008-08-01 2011-08-31 约翰.霍普金斯大学 Psma-结合剂及其用途
CN103275178A (zh) * 2013-05-21 2013-09-04 首都医科大学 正十二酸-rgd-正十四醇介导利尼法尼靶向脂质体的制备及抗肿瘤活性评价

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572200B1 (fr) * 2002-12-12 2011-08-17 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
CN102153551B (zh) * 2010-04-02 2012-04-25 济南海乐医药技术开发有限公司 基于吲唑或氮杂吲唑的双芳基脲或硫脲类结构抗肿瘤药物
US20120190563A1 (en) * 2010-05-07 2012-07-26 Abbott Laboratories Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
JP6469661B2 (ja) * 2013-06-11 2019-02-13 カラ ファーマシューティカルズ インコーポレイテッド 尿素誘導体及びその使用
CN104725319A (zh) * 2015-03-11 2015-06-24 西安交通大学 一种具有抗肿瘤活性的1h-吲唑-3-氨基联苯脲类化合物及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072581A (zh) * 2004-10-05 2007-11-14 健泰科生物技术公司 具有减少的毒性的治疗剂
CN102171187A (zh) * 2008-08-01 2011-08-31 约翰.霍普金斯大学 Psma-结合剂及其用途
US20100143296A1 (en) * 2008-12-10 2010-06-10 Auspex Pharmaceuticals, Inc. Podophyllotoxin inhibitors of topoisomerase ii
CN103275178A (zh) * 2013-05-21 2013-09-04 首都医科大学 正十二酸-rgd-正十四醇介导利尼法尼靶向脂质体的制备及抗肿瘤活性评价

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMUEL R. DENMEADE等: ""Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy"", 《SCI TRANSL MED》 *

Also Published As

Publication number Publication date
US20190365711A1 (en) 2019-12-05
JP6999960B2 (ja) 2022-01-19
US11712434B2 (en) 2023-08-01
WO2018090976A1 (zh) 2018-05-24
JP2019535751A (ja) 2019-12-12
CN110167554B (zh) 2023-05-23
EP3542796B1 (en) 2024-03-27
EP3542796A4 (en) 2020-08-19
WO2018090974A1 (zh) 2018-05-24
EP3542796A1 (en) 2019-09-25

Similar Documents

Publication Publication Date Title
RU2711077C2 (ru) Соли ингибитора киназы рецептора эпидермального фактора роста
CN104053439A (zh) 1-(5,6-二氯-1h-苯并[d]咪唑-2-基)-1h-吡唑-4-羧酸的葡甲胺盐制剂
WO2013007184A1 (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
US11767319B2 (en) Crystalline forms of a selective c-kit kinase inhibitor
EP3560918A1 (en) Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine
CN112047993A (zh) 一种α-葡萄糖苷酶抑制剂及其用途
CN110167554A (zh) 一种具有抗癌作用的化合物及其制备方法和应用
KR20180110151A (ko) 치환된 아미노 6원 질소 헤테로고리계 화합물 및 이의 제조와 용도
TW565559B (en) Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them
CN108047207A (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
EP1560818A1 (en) Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
CN112243437A (zh) 含丙烯酰基的核转运调节剂及其用途
CN110167917B (zh) 一种具有抗癌作用的化合物及其制备方法和应用
CN112920167B (zh) 靶向fgfr和hdac的双靶点抑制剂及其制备方法和应用、药物组合物及药剂
TWI703134B (zh) 一種具有抗癌作用的化合物及其製備方法和應用（二）
TWI721255B (zh) 一種具有抗癌作用的化合物及其製備方法和應用（一）
CN109896986B (zh) 木脂素类天然产物4-o-甲基三白草醇的结构简化物，其制法和其药物组合物与用途
WO2019184919A1 (zh) 一种含有金刚烷的化合物及其在治疗癌症中的用途
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
CN111039880A (zh) 咪康唑及其衍生物作为tgr5激动剂的应用
US20130164218A1 (en) Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents
WO2021164789A1 (zh) 一种吡唑并嘧啶类化合物的晶型及其应用
CN116120327A (zh) β-榄香烯13,14-位对称的双取代衍生物及其制备方法和应用
KR20240042482A (ko) Ep4 길항제 화합물, 이의 염, 다형체 및 용도
CN117820340A (zh) Atr抑制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 100176 101, Floor 1, Building 6, Zone 3, Yard 7, Liangshuihe 1st Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing (Yizhuang Cluster, High-end Industrial Zone, Beijing Pilot Free Trade Zone)

Applicant after: 3D MEDICINES, Ltd.

Address before: 1201, Floor 12, Building 3, Yard 22, Ronghua Middle Road, Economic and Technological Development Zone

Applicant before: 3D MEDICINES, Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant